The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Colorectal cancer and embryonal testicular cancer as well as several cases of prostate, breast, thyroid and gastric cancers showed moderate cytoplasmic positivity with a granular pattern. Remaining malignant cells were weakly stained or negative.
Several cases of malignant lymphomas, colorectal, ovarian, endometrial and pancreatic cancers showed moderate to strong cytoplasmic immunoreactivity. Additional nuclear staining as observed in a few cases. Remaining malignancies were in general weakly stained or negative.
Malignant melanomas, thyroid, renal and prostate cancers as well as several endometrial and colorectal cancers showed moderate cytoplasmic positivity. Remaining malignant cells were in general weakly stained or negative.
Most malignant cells displayed weak to moderate cytoplasmic and nuclear immunoreactivity. Most cases of malignant carcinoid and head & neck cancers as well as several skin cancers were weakly stained or negative.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
